1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 40 to 90
Sponsor: Pharmaceutical / Industry
Protocol IDs: AVO108943, NCT00470834
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 50 and over
Sponsor: Other
Protocol IDs: G050103, NCT00295802
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Prostate4809, P01 CA098012, NCT00583492
|
|
4.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 40 to 75
Sponsor: NCI
Protocol IDs: UIC-2006-0706, 2006-0706, NCT00765479
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0232, CTSU, NCT00063882
|
|
6.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: NCI
Protocol IDs: FCCC-03028, NCT00084552
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 30 and over
Sponsor: Other
Protocol IDs: 05-043, NCT00116142
|
|
8.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 05-007, NCT00142506
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 553, NCT00132301
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 40 to 80
Sponsor: Other
Protocol IDs: 04-8-10, NCT00241384
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: No age specified
Sponsor: Other
Protocol IDs: 05-8-4, NCT00243646
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: No age specified
Sponsor: Other
Protocol IDs: 05-8-3, NCT00247312
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0521, NCT00288080
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: ROLL-GUP-0205-1, UCLA-0507059-01, NCT00336934
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0415, NCT00331773
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2003-0819, NCT00388804
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-90203, NCT00430183
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: NCI
Protocol IDs: CAN-NCIC-CTG-PR11, NCIC-PR.11, PR11, CALGB-140602, SWOG-PR11, NCT00499174
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 40 to 90
Sponsor: Other
Protocol IDs: 02-4407-V04, NCT00486499
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XRP6976J_3503, EudraCT#:2007-000323-17, NCT00514917
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0534, RTOG 0534, NCT00567580
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4320C00015, NCT00626548
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: ID00-381, NCT00667888
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 40 to 80
Sponsor: Other
Protocol IDs: FSI-003, NCT00772317
|
|
25.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: INST 0808, NCT00809458
|
